Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does ARIPIPRAZOLE Cause Product communication issue? 19 Reports in FDA Database

Sharpen Your Memory & Focus Naturally

NeuroZoom — 35 clinically studied ingredients. No stimulants. Pure brain support.

Boost Your Brain

According to the FDA Adverse Event Reporting System (FAERS), 19 reports of Product communication issue have been filed in association with ARIPIPRAZOLE (Aripiprazole). This represents 0.0% of all adverse event reports for ARIPIPRAZOLE.

19
Reports of Product communication issue with ARIPIPRAZOLE
0.0%
of all ARIPIPRAZOLE reports
1
Deaths
5
Hospitalizations

How Dangerous Is Product communication issue From ARIPIPRAZOLE?

Of the 19 reports, 1 (5.3%) resulted in death, 5 (26.3%) required hospitalization, and 1 (5.3%) were considered life-threatening.

Is Product communication issue Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for ARIPIPRAZOLE. However, 19 reports have been filed with the FAERS database.

What Other Side Effects Does ARIPIPRAZOLE Cause?

Drug ineffective (5,566) Off label use (5,473) Product use in unapproved indication (4,792) Weight increased (4,636) Anxiety (3,076) Suicide attempt (2,796) Suicidal ideation (2,618) Condition aggravated (2,157) Insomnia (2,147) Akathisia (2,107)

What Other Drugs Cause Product communication issue?

EVOLOCUMAB (2,341) SEMAGLUTIDE (842) ERENUMAB-AOOE (598) SOMATROPIN (350) PEGFILGRASTIM (333) ETANERCEPT (122) ALBUTEROL (121) NIRMATRELVIR\RITONAVIR (70) DENOSUMAB (68) LEVODOPA (61)

Which ARIPIPRAZOLE Alternatives Have Lower Product communication issue Risk?

ARIPIPRAZOLE vs ARIPIPRAZOLE LAUROXIL ARIPIPRAZOLE vs ARIXTRA ARIPIPRAZOLE vs ARMODAFINIL ARIPIPRAZOLE vs AROMASIN ARIPIPRAZOLE vs ARSENIC TRIOXIDE

Related Pages

ARIPIPRAZOLE Full Profile All Product communication issue Reports All Drugs Causing Product communication issue ARIPIPRAZOLE Demographics